TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02737267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderately high protein diet
Description: After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low fat diet
Description: After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat
Study: NCT03449251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
Study: NCT00571675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101, prednisone and docetaxel
Description: docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, prednisone and docetaxel
Description: docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
Study: NCT03449251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
Study: NCT02719977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX5461
Study: NCT04574089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Baofukang Suppository 7 days
Description: Experimental: Baofukang Suppository 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Baofukang Suppository 14 days
Description: Experimental: Baofukang Suppository 14 days
Study: NCT01288690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: 3, 1-1/2 hour sessions, individual, meeting weekly.
Study: NCT03092427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Dietary Supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03759080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mental practice
Description: training of mental practice to do the pattern of proprioceptive neuromuscular facilitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: proprioceptive neuromuscular facilitation
Description: upper limb Pattern: Flexion -Abduction- External rotation
Study: NCT03175796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Mental Health-Home Visiting
Description: Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
Study: NCT03982524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy for patients with multiple somatoform symptoms
Description: Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
Study: NCT01994213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib 25 mg p.o. qd
Study: NCT00596219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: celecoxib
Study: NCT02672241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
Study: NCT03449251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
Study: NCT01748370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in hypogonadal men

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation in eugonadal men

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hypogonadal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eugonadal
Study: NCT01629550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin disinfection prior catheter insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin disinfection prior catheter insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin disinfection prior catheter insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin disinfection prior catheter insertion
Study: NCT04126434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mask
Description: facemask

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: mask
Description: facemask
Study: NCT01346865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1tablet bid
Study: NCT01719380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study: NCT01611675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: take orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: take orally, once daily
Study: NCT00974311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: MDV3100, 160 mg orally per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04474340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalscent Plasma
Description: The source convalescent plasma is typically collected from individuals who have recovered from COVID-19 which contains antibodies titer against SARS-CoV-2 and is administered to patients with COVID-19. Donor eligibility criteria and qualification are based on American Accredited Blood Banks ( AABB) standards , including questionnaires and relevant transfusion-transmitted infections testing are performed. Furthermore, pathogen inactivation will be performed for each unit, CCP was only collected from individuals who meet all donor eligibility requirements (21 CFR 630.10 and 21 CFR 630.15). Donors must be found positive at a diagnostic test of nasopharyngeal swab at the time of illness and positive serological test for SARS-CoV-2 antibodies after recovery. All donors should have negative HLA antibodies.
Study: NCT03155711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNC group
Description: Positive pressure plus supplemental oxygen through a high flow nasal oxygen device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard group
Description: Supplemental oxygen through venturi mask
Study: NCT03158207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waters Mask
Description: All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Mask
Description: Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
Study: NCT03102762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
Study: NCT03326440

Intervention type: OTHER
Group type: OTHER
Intervention: VERT system
Description: 3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)

Intervention type: OTHER
Group type: OTHER
Intervention: VERT system
Description: 3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
Study: NCT00663650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent Section Control
Description: After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Section Control
Description: After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
Study: NCT02904746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make It!
Description: The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
Study: NCT02654639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 Twice a day by mouth day 1-5 and 8-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion once every 14 days
Study: NCT01248897

Intervention type: OTHER
Intervention: This study is non-interventional study, so this section is not applicable.
Description: This study is non-interventional study, so this section is not applicable.
Study: NCT03691636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyelash prostheses
Description: Eyelash prostheses are essentially specialized eyelash extensions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5.0% Lifitegrast Ophthalmic Solution
Description: 5.0% Lifitegrast Ophthalmic Solution
Study: NCT03318263

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: next-generation sequencing (NGS)
Description: ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
Study: NCT05022498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 60 min treadmill exercise performed at 60% of maximum oxygen uptake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 60 min treadmill exercise performed at 60% of maximum oxygen uptake.
Study: NCT00960193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seville Orange Juice
Description: 240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
Study: NCT02938468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Any surgical intervention aim at treating chronic subdural hematoma
Study: NCT01324102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga therapy
Description: For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
Study: NCT02501824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anthroposophic therapeutic speech
Description: anthroposophic therapeutic speech

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anthroposophic therapeutic speech
Description: anthroposophic therapeutic speech
Study: NCT01210638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone
Description: 10 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone
Description: 10 mg tablet
Study: NCT02888834

Intervention type: OTHER
Intervention: Adverse drug reaction
Study: NCT04221334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electric Toothbrush
Description: Electric Toothbrush used to remove dental plaque and resolve gingivitis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electric Toothbrush
Description: Electric Toothbrush used to remove dental plaque and resolve gingivitis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral health care application
Description: phone application that shows the user brushing efficiency real time
Study: NCT02560168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoVista device
Description: MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography
Description: Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography
Study: NCT03238417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-Based Quality Improvement
Description: Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
Study: NCT04222543

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RGD PET/CT
Description: Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RGD PET/CT
Description: Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
Study: NCT02081989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal denervation
Study: NCT03908346

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest
Description: a decision aid has been created that is a four page document meant to support surrogate decision makers for comatose survivors of cardiac arrest
Study: NCT03821038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT107
Description: IV twice a week at 10µg/kg for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV twice a week at the same volume for 3 weeks
Study: NCT01192165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Investigational small molecule targeted therapy (MEK1/2 inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Investigational small molecule targeted therapy (MEK1/2 inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Investigational small molecule targeted therapy (MEK1/2 inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Investigational small molecule targeted therapy (MEK1/2 inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Investigational small molecule targeted therapy (MEK1/2 inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Investigational small molecule targeted therapy (MEK1/2 inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Small molecule targeted therapy (EGFR inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy
Study: NCT01952652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group N:Naproxen sodium
Description: drug will be given 60 minutes before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group NC :naproxen sodium codeine phosphate
Description: drug will be given 60 minutes before surgery
Study: NCT00001566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: 3 syringes containing 1 x 10\^6peptide pulsed dendritic cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indinavir sulfate
Description: Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
Study: NCT02779569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine